Comment Period for New DEA Telehealth Rules Through March 31

As you may know, in late February, the Drug Enforcement Administration announced proposed permanent rules for the prescribing of controlled medications via telemedicine. Members can learn more about these general rules here, and review the formal proposed rules here

There is a 30-day public comment period which ends on March 31, 2023, so if you are interested in providing input, you may do so by clicking here and clicking on the Green “Submit a Formal Comment” button at the top of the screen. Please keep in mind that all comments received, including attachments and other supporting materials, are considered part of the public record and will be made available by DEA for public inspection online, here.

The proposed rules include:

  • Requirement to review Prescription Drug Monitoring Program data prior to prescribing buprenorphine under the authority the regulations would grant. 
  • Requirement for patient to receive a medical evaluation meeting certain requirements (in-person) within 30 days of being prescribed buprenorphine for the induction of OUD treatment in order to obtain an additional supply of buprenorphine.
  • Requirements for enhanced recordkeeping. 
Share this post:

Comments on "Comment Period for New DEA Telehealth Rules Through March 31"

Comments 0-5 of 0

Please login to comment